Why People Are Losing Faith in Healthcare
Episode
47 min
Read time
2 min
Topics
Health & Wellness, Investing, Fundraising & VC
AI-Generated Summary
Key Takeaways
- ✓GLP-1 pricing trajectory: Lilly's Zepbound dropped 60% in price since launch, now available at $399/month through Lilly Direct, bypassing pharmacy benefit managers. The oral version Foundeo starts at $159/month. Medicare seniors gain access at $50/month starting July 1, opening the market to 70 million additional patients.
- ✓GLP-1 applications beyond obesity: Clinical trials show GLP-1 drugs reduce chronic inflammation, with Lilly's triple-acting retatrutide demonstrating the strongest pharmacological pain reduction ever recorded for knee arthritis. Trials also confirm reduced alcohol consumption, with a phase-three study targeting alcohol use disorder underway under the drug name brinapatide.
- ✓Pharma competitive advantage through speed: Lilly cut R&D cycle time by five years — from 11 years to roughly six — while competitors stayed flat. Since U.S. patents last 20 years, this creates significantly more protected market time per drug. Lilly identifies target markets before they become obvious, committing to obesity research in 2018 when no competitors were investing.
- ✓AI in drug discovery — realistic timeline: Current LLMs excel at synthesizing existing knowledge but fail at drug discovery because humans have mapped only 10–20% of human biology. Lilly has automated roughly 20 of approximately 1,000 preclinical steps using AI. Meaningful acceleration requires building biological datasets that don't yet exist, making a realistic impact timeline 5–10 years out.
- ✓Obesity as fiscal policy: Obesity-related healthcare costs total approximately $1.4 trillion annually — roughly equal to the entire proposed U.S. defense budget. With 70% of Americans overweight or obese versus Japan's 4% obesity rate, the U.S. spends $13,050 per person on healthcare versus Japan's $5,500, suggesting obesity reduction is a prerequisite for meaningful deficit reduction.
What It Covers
Scott Galloway interviews Eli Lilly CEO David Ricks on the company's first-ever trillion-dollar healthcare valuation, GLP-1 drug technology's expanding applications beyond weight loss, the broken U.S. healthcare pricing system, Lilly's competitive advantages in pharma R&D, and why AI remains overhyped in drug discovery.
Key Questions Answered
- •GLP-1 pricing trajectory: Lilly's Zepbound dropped 60% in price since launch, now available at $399/month through Lilly Direct, bypassing pharmacy benefit managers. The oral version Foundeo starts at $159/month. Medicare seniors gain access at $50/month starting July 1, opening the market to 70 million additional patients.
- •GLP-1 applications beyond obesity: Clinical trials show GLP-1 drugs reduce chronic inflammation, with Lilly's triple-acting retatrutide demonstrating the strongest pharmacological pain reduction ever recorded for knee arthritis. Trials also confirm reduced alcohol consumption, with a phase-three study targeting alcohol use disorder underway under the drug name brinapatide.
- •Pharma competitive advantage through speed: Lilly cut R&D cycle time by five years — from 11 years to roughly six — while competitors stayed flat. Since U.S. patents last 20 years, this creates significantly more protected market time per drug. Lilly identifies target markets before they become obvious, committing to obesity research in 2018 when no competitors were investing.
- •AI in drug discovery — realistic timeline: Current LLMs excel at synthesizing existing knowledge but fail at drug discovery because humans have mapped only 10–20% of human biology. Lilly has automated roughly 20 of approximately 1,000 preclinical steps using AI. Meaningful acceleration requires building biological datasets that don't yet exist, making a realistic impact timeline 5–10 years out.
- •Obesity as fiscal policy: Obesity-related healthcare costs total approximately $1.4 trillion annually — roughly equal to the entire proposed U.S. defense budget. With 70% of Americans overweight or obese versus Japan's 4% obesity rate, the U.S. spends $13,050 per person on healthcare versus Japan's $5,500, suggesting obesity reduction is a prerequisite for meaningful deficit reduction.
Notable Moment
Ricks revealed that Lilly's blockbuster drug tirzepatide was the 700th formulation tested, and the first human candidate failed — requiring 500 additional versions before finding a superior compound, illustrating why AI cannot yet replace physical laboratory experimentation in drug development.
Episode Transcript
Cheating on your partner is a huge breach of trust. All of the the pain and the guilt and the reality of what was happening hit me just like a tidal wave all at once. Why do people cheat? And why does it make us so mad even when we are not the ones it's happening to? That's this week on Explain It To Me. New episodes, Sundays, wherever you get your podcasts. Megan Rapinoe here. This week is our last regular episode of A Touch More before I kick off a limited series, A Touch More, The Beautiful Game, a special series for the World Cup featuring in-depth interviews with some of soccer's biggest stars. But for this week, we are closing out the era with a special compilation episode featuring our absolute favorite moments and themes from our last 90 episodes of A Touch More. Check out the latest episode of A Touch More wherever you get your podcasts and on YouTube. Episode 399. Three ninety nine is the world's most famous and most photographed grizzly bear. In 1999, The Sopranos premiered. So I got my boss a tie and a dildo for Christmas. And if he doesn't like the tie, he can go fuck himself. That's an actual joke from the series The Sopranos. Little media history keeping you keeping you up on the greatest nostalgia of what is arguably the second greatest TV show behind Breaking Bad. Enough already. Go. Go. Go. Welcome to the three hundred ninety ninth episode of the Prop GPOG. What's happening? In today's episode, we speak with David Ricks, chair and CEO of Eli Lilly and Company. So each year, I do a prediction stack. It's our most sought after content. And I pick a technology of the year. In the last two years, I've only had one technology repeat. That's right. And it's not AI. What technology do I believe is gonna have a more profound impact on the world than AI? GLP ones. I just I think this technology every time new data on the technology or, you know, evidence on the technology comes out, it's oh, it, you know, it makes you wanna eat more kale or it makes you nicer to your pets. I mean, the this thing is just wild. The way I describe it is scaffolding on our instincts. Our our instincts haven't caught up with the institutional production of things that we traditionally were in short supply and that we developed cravings and even addictions for. And GLP ones are essentially scaffolding on our instincts. Anyways, I'm a big GLP one fan, so I'm excited about that. Anyways, with that, I hope you enjoy our conversation with Dave Ricks. Dave, let's bust right into it. Eli Lilly is the first health care company to reach a trillion dollar valuation, and it's also turning a 150. Talk to us about Eli Lilly. Yeah. Sure. Well, this is a important year. As you said, we turned …
Get the full transcript (8,712 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 44-minute episode.
Get The Prof G Pod summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from The Prof G Pod
The Relationship Habit That Makes You Unhappy + Living Far From Aging Parents
Sep 2 · 17 min
David Senra
Tobi Lütke, Shopify
Jan 18
More from The Prof G Pod
China Decode: Is China Winning the Global AI Trust War?
Sep 1 · 41 min
Pivot
Holiday Spending Surge, Fed Chair Future, and Melania's Production Company
Dec 2
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links. As an Amazon Associate, SignalCast earns from qualifying purchases.
Products
by Eli Lilly
“Ricks revealed that Lilly's blockbuster drug tirzepatide was the 700th formulation tested, and the first human candidate failed.”
by Eli Lilly
“Trials also confirm reduced alcohol consumption, with a phase-three study targeting alcohol use disorder underway under the drug name brinapatide.”
by Eli Lilly
“Lilly's triple-acting retatrutide demonstrating the strongest pharmacological pain reduction ever recorded for knee arthritis.”
More from The Prof G Pod
We summarize every new episode. Want them in your inbox?
The Relationship Habit That Makes You Unhappy + Living Far From Aging Parents
China Decode: Is China Winning the Global AI Trust War?
Navigating a Mid-Career Crisis, And How to Spend Your 20s
China Decode: Taiwan's Record Defense Budget, Evergrande's Life Sentence, and China's Robot Boom
No Mercy / No Malice: I Disagree
Similar Episodes
Related episodes from other podcasts
David Senra
Jan 18
Tobi Lütke, Shopify
Pivot
Dec 2
Holiday Spending Surge, Fed Chair Future, and Melania's Production Company
Pivot
Jun 30
Comcast Splits, OpenAI Weighs IPO Delay, and Buttigieg Targeted
The Daily (NYT)
Jun 7
Scott Pelley on His Firing and the ‘Massacre’ at ’60 Minutes’
Pivot
May 8
OpenAI Trial "Soap Opera," ChatGPT's Stock Picks, and Remembering Ted Turner
Explore Related Topics
This podcast is featured in Best Business Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into The Prof G Pod.
Every Monday, we deliver AI summaries of the latest episodes from The Prof G Pod and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime